{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T21:19:56Z","timestamp":1761167996424,"version":"build-2065373602"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.ymgme.2012.08.009","type":"journal-article","created":{"date-parts":[[2012,8,17]],"date-time":"2012-08-17T11:30:21Z","timestamp":1345203021000},"page":"521-525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Minimal disease activity in Gaucher disease: Criteria for definition"],"prefix":"10.1016","volume":"107","author":[{"given":"Maja","family":"Di Rocco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Generoso","family":"Andria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Bembi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Carubbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiorina","family":"Giona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Giuffrida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Linari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelina","family":"Sibilio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Spina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Domenica","family":"Cappellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2012.08.009_bb0005","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"Gaucher disease","author":"Grabowski","year":"2006"},{"key":"10.1016\/j.ymgme.2012.08.009_bb0010","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrm1423","article-title":"The cell biology of lysosomal storage disorders","volume":"5","author":"Futerman","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0015","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5years of treatment: a report from the Gaucher Registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0020","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.21280","article-title":"A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase","volume":"83","author":"Weinreb","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0025","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.beha.2010.07.007","article-title":"Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing","volume":"23","author":"Coustan-Smith","year":"2010","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0030","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.seminhematol.2011.05.002","article-title":"Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance","volume":"48","author":"Pott","year":"2011","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0035","first-page":"868","article-title":"Outcomes from the Patient Perspective Workshop at OMERACT 6","volume":"30","author":"Kirwan","year":"2003","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0040","first-page":"2016","article-title":"Minimal disease activity for rheumatoid arthritis: a preliminary definition","volume":"32","author":"Wells","year":"2005","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0045","first-page":"52","article-title":"Low disease activity state in rheumatoid arthritis: concepts and derivations of minimal disease activity","volume":"24","author":"Wells","year":"2006","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0050","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/art.22895","article-title":"Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis","volume":"57","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0055","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3324\/haematol.12379","article-title":"A new severity index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease","volume":"93","author":"Di Rocco","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.ymgme.2012.08.009_bb0060","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/GIM.0b013e3181c39194","article-title":"A validated disease severity scoring system for adults with type 1 Gaucher disease","volume":"12","author":"Weinreb","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0065","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2105\/AJPH.74.9.979","article-title":"Consensus methods: characteristics and guidelines for use","volume":"74","author":"Fink","year":"1984","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.ymgme.2012.08.009_bb0070","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00005792-199211000-00002","article-title":"Gaucher disease: clinical, laboratory, radiologic and genetic features of 53 patients","volume":"71","author":"Zimran","year":"1992","journal-title":"Medicine"},{"key":"10.1016\/j.ymgme.2012.08.009_bb0075","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/10245330500067181","article-title":"Survey of hematological aspects of Gaucher disease","volume":"10","author":"Zimran","year":"2005","journal-title":"Hematology"},{"key":"10.1016\/j.ymgme.2012.08.009_bb0080","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease","volume":"160","author":"Charrow","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0085","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1023\/A:1012496514170","article-title":"Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses","volume":"24","author":"Cox","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0090","first-page":"1","article-title":"Nutritional anaemias. Report of a WHO Scientific Group","volume":"405","author":"Blanc","year":"1968","journal-title":"WHO Tech. Rep. Ser."},{"year":"2009","series-title":"Hematology \u2014 Basic Principles and Practice","key":"10.1016\/j.ymgme.2012.08.009_bb0095"},{"key":"10.1016\/j.ymgme.2012.08.009_bb0100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0887-7963(87)70022-4","article-title":"Platelet transfusion therapy","volume":"1","author":"National Institutes of Health Consensus Conference","year":"1987","journal-title":"Transfus. Med. Rev."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0105","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/(SICI)1096-8652(199906)61:2<103::AID-AJH5>3.0.CO;2-V","article-title":"Platelet function abnormalities in Gaucher disease patients","volume":"61","author":"Gillis","year":"1999","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0110","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1046\/j.1365-2141.1997.d01-2076.x","article-title":"Coagulation abnormalities in type 1 Gaucher disease are due to low grade activation and can be partly restored by enzyme supplementation therapy","volume":"96","author":"Hollak","year":"1997","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0115","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1148\/radiology.160.3.3526400","article-title":"Gaucher disease: sonographic appearance of the spleen","volume":"160","author":"Hill","year":"1986","journal-title":"Radiology"},{"key":"10.1016\/j.ymgme.2012.08.009_bb0125","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1359\/jbmr.061004","article-title":"Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease","volume":"22","author":"Wenstrup","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0130","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2292020296","article-title":"Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging \u2014 initial experience","volume":"229","author":"Maas","year":"2003","journal-title":"Radiology"},{"key":"10.1016\/j.ymgme.2012.08.009_bb0135","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2214\/AJR.06.1410","article-title":"Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher's disease using the bone marrow burden score","volume":"188","author":"Robertson","year":"2007","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0140","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1006\/bcmd.2002.0511","article-title":"Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients","volume":"28","author":"Poll","year":"2002","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0145","doi-asserted-by":"crossref","first-page":"802","DOI":"10.2106\/00004623-198668060-00002","article-title":"Evaluation of Gaucher disease using magnetic resonance imaging","volume":"68","author":"Rosenthal","year":"1986","journal-title":"J. Bone Joint Surg. Am."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0150","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s002560100375","article-title":"Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results","volume":"30","author":"Poll","year":"2001","journal-title":"Skeletal Radiol."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0155","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s002560000276","article-title":"Bone marrow response in treated patients with Gaucher disease: evaluation by T1-weighted magnetic resonance images and correlation with reduction in liver and spleen volume","volume":"29","author":"Terk","year":"2000","journal-title":"Skeletal Radiol."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0160","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/00004728-200209000-00031","article-title":"Vertebra disc ratio as a parameter for bone marrow involvement and its application in Gaucher disease","volume":"26","author":"Vlieger","year":"2002","journal-title":"J. Comput. Assist. Tomogr."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0165","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/jbmr.5650111125","article-title":"Bone density in Type 1 Gaucher disease","volume":"11","author":"Pastores","year":"1986","journal-title":"J. Bone Miner. Res."},{"year":"2004","series-title":"WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level","key":"10.1016\/j.ymgme.2012.08.009_bb0170"},{"key":"10.1016\/j.ymgme.2012.08.009_bb0175","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1586\/epr.09.54","article-title":"Gaucher disease: a model disorder for biomarker discovery","volume":"6","author":"Boot","year":"2009","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.ymgme.2012.08.009_bb0180","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1023\/A:1012492429191","article-title":"Clinically relevant therapeutic endpoints in type I Gaucher disease","volume":"24","author":"Hollak","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0185","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10545-011-9308-6","article-title":"Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies","volume":"34","author":"Aerts","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0190","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1172\/JCI117084","article-title":"Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease","volume":"93","author":"Hollak","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0195","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/BF02436762","article-title":"Elevated plasma chitotriosidase activity in various lysosomal storage disorders","volume":"18","author":"Guo","year":"1995","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0200","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1161\/01.ATV.19.3.687","article-title":"Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages","volume":"19","author":"Boot","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0205","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cca.2009.09.034","article-title":"Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis","volume":"411","author":"Boot","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2012.08.009_bb0210","first-page":"10","article-title":"Molecular and biochemical abnormalities of Gaucher disease: chitotriosidase, a newly identified biochemical marker","volume":"32","author":"Aerts","year":"1995","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0215","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1651-2227.2005.tb02110.x","article-title":"Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases","volume":"94","author":"Aerts","year":"2005","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0220","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1651-2227.2005.tb02109.x","article-title":"Biomarkers in lysosomal storage diseases: a review","volume":"94","author":"Cox","year":"2005","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0225","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bcmd.2005.05.005","article-title":"Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease","volume":"35","author":"Deegan","year":"2005","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0230","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2003-05-1612","article-title":"Marked elevation of the chemokine CCL18\/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention","volume":"103","author":"Boot","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2012.08.009_bb0235","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10545-008-0779-z","article-title":"Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring","volume":"31","author":"Cox","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0240","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bcmd.2009.09.005","article-title":"CCL18 is an alternative marker in Gaucher and Niemann\u2013Pick disease with chitotriosidase deficiency","volume":"44","author":"Chang","year":"2010","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0245","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1651-2227.2007.00641.x","article-title":"Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease","volume":"97","author":"Aerts","year":"2008","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0250","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.bbadis.2007.04.002","article-title":"Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease","volume":"1772","author":"van Breemen","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2012.08.009_bb0255","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bcmd.2010.10.010","article-title":"Potential biomarkers of osteonecrosis in Gaucher disease","volume":"46","author":"Pavlova","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0260","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10545-010-9271-7","article-title":"Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity","volume":"34","author":"Stein","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.08.009_bb0265","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","article-title":"Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response","volume":"118","author":"Dekker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2012.08.009_bb0270","first-page":"299","article-title":"Gaucher disease: clinical profile and therapeutic developments","volume":"4","author":"Cox","year":"2010","journal-title":"Biologics"},{"key":"10.1016\/j.ymgme.2012.08.009_bb0275","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin. Hematol."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719212003095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719212003095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:20:14Z","timestamp":1761088814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719212003095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S1096719212003095"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2012.08.009","relation":{},"ISSN":["1096-7192"],"issn-type":[{"type":"print","value":"1096-7192"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimal disease activity in Gaucher disease: Criteria for definition","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2012.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}